When analyzing the results of the first Trial to Assess Chelation Therapy (TACT), researchers found that a subgroup of patients with diabetes who received EDTA chelation had fewer cardiovascular events than patients who did not receive EDTA chelation. This was not what researchers were expecting to find.

The Black Swan: The first Trial to Assess Chelation Therapy (TACT) represents a rare occurrence in large randomized clinical trials, something very unexpected, which may have far-reaching consequences. In his book “The Black Swan: the Impact of the Highly Improbable,” Nassim Nicholas Taleb termed such occurrences “black swan events,” and convincingly discussed how such events can alter the course of science.

An article in the American Heart Association’s journal Circulation: Cardiovascular Quality and Outcomes has the details: The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)